Insights & news

Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

  • 13/07/2020
  • Articles

The pharmaceutical sector continues to draw competition scrutiny across Europe.
United Kingdom
On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.
Aspen had already acknowledged wrongdoing and agreed to pay a fine of GBP 2.1 million. It also offered commitments and promised to pay compensation to the National Health Service (see, Van Bael & Bellis Life Sciences News Alert of 4 October 2019). Tiofarma has now agreed to pay a fine of its own while the public information suggests that Amilco escaped punishment.  
European Commission
Aspen also found itself in the spotlight of the European Commission (the Commission) which indicated that it expected to wrap up its excessive pricing investigation of the company still this year (see, Van Bael & Bellis Life Sciences News Alert of 16 May 2017). The Commission added that the same schedule applied to its inquiry into alleged pay-for-delay practices suspected of impeding the market entry of generic modafinil, a sleeping disorder medicine. Teva is the direct target of this procedure but is also challenged indirectly in the guise of its subsidiary Cephalon (see, Van Bael & Bellis Life Sciences News Alerts of 17 July 2017 and 10 June 2020).
The Commission stated its intentions in its Report on Competition Policy 2019 which it published on 9 July 2020 (see, attached staff working document, at p. 77 – the Commission’s main report is also attached).


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 31/07/2020
    • Articles

    British Medical Journal Publishes Critical Review of Orphan Medicines Rules Ahead of Release of European Commission's Own Studies

    As part of the preparatory work for its Pharmaceutical Strategy for Europe which is due in the fourth quarter of 2020, the European Commission (the Commission) is expected to publish shortly an external study and own work assessing the regulatory framework governing orphan medicines and the paediatric rules.

    Read more
    • 28/07/2020
    • Articles

    US President Signs Executive Order Implementing International Pricing Index Model

    On 24 July 2020 the US President signed four executive orders designed to lower medicine prices in the United States (see, attached press release). One of these orders, which has not yet been made publicly available, implements a form of international reference pricing and “take[s] action to ensure that the Medicare program and seniors pay no more for [a series of costly medicines] than any economically comparable OECD country, ending foreign countries’ free loading off the backs of American taxpayers and pharmaceutical investments” (the “International Pricing Index Model” or “IPI Model”).

    Read more
    • 23/07/2020
    • Articles

    Belgium - Belgian Competition Authority Offers Guidance on Mergers of Local Hospital Networks

    On 22 July 2020, the Belgian Competition Authority (BCA) published a note (the Note) which discusses the application of the Belgian merger control rules to the creation of local hospital networks (locoregionale ziekenhuisnetwerken; réseaux hospitaliers locorégionaux – see the attached Note and press release in different language versions).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *